Skip to content

Citius Oncology, Inc. CTOR Number of Exercisable Options

Number of Exercisable Options at other companies

Merck & Co. logo
Merck & Co.MRK
9.3M+2.9%
Delcath Systems logo
Delcath SystemsDCTH
5.4M+39.8%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s number of exercisable options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s number of exercisable options?
Citius Oncology, Inc. (CTOR) reported number of exercisable options of 11.5M in Q1 2026.
How has Citius Oncology, Inc.'s number of exercisable options changed year-over-year?
Citius Oncology, Inc.'s number of exercisable options increased by 124.0% year-over-year, from 5.1M to 11.5M.
What does number of exercisable options mean?
The number of share-based payment options that have met all vesting requirements and are currently eligible for exercise by the holders. This represents the portion of the equity incentive pool that could be converted into common stock immediately. It is a critical component for calculating fully diluted share counts.